Respiratory
Our advanced image analysis technology allows segmentation of lung structures like airways and blood vessels as well as detection of abnormalities in the lung parenchyma linked to multiple lung diseases. The quantification of these segmentations allows to measure and follow-up the presence and the extent of conditions like COVID-19, influenza, ILDs, COPD, asthma, and others.
We demonstrated that radiomics quantifications are useful tools in optimizing the clinical drug development trajectory, daily patient management or to generate additional insights in respiratory research.
During the pandemic conditions, Radiomics.bio developed COVIA, an AI-algorithm that could detect a COVID-19 from CT scans and is currently actively involved in research on fibrosis, pulmonary embolism & hypertension, and emphysema.
![[:swvar:ufile:1:description:]](/swfiles/files/logo-radiomics.svg?nc=1709282693){kind=logo}